Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer
- PMID: 28562469
- DOI: 10.1097/IGC.0000000000000993
Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer
Abstract
Purpose: The aim of this study was to determine the incidence and risk factors for gynecological cancer as second malignancy (SM) after treatment of breast cancer (BC).
Methods and materials: Between January 1985 and December 2007, a total of 2756 patients with BC were analyzed for gynecological cancers as an SM. Analysis was carried out for patient-, disease-, and treatment-related characteristics. The Cox proportional hazards regression model was used to estimate the relative risk of gynecologic malignancies.
Results: The median age at BC diagnosis was 49 years and median follow-up of 14 years. In total, 25 cases of gynecological cancer were noted with an incidence of 0.9%. We observed 9 ovarian and endometrium (0.3%) as well as 7 uterine cervix (0.25%) cancers. Family history of BC was the most significant risk factor for SM (relative risk, 7.4; 95% confidence interval, 3.03-18.28; P<0.001). Women with a family history of BC had a higher incidence of endometrial (12%) and ovarian (16%) cancer compared with those who have no family history (0.1%, P = 0.003). Statistically significant higher incidence of endometrial cancer was seen in patients undergoing hormonal therapy (0.4%) as compared with those who are not undergoing hormonal therapy (0.1%, P = 0.001). Most of the endometrial (88.9%) and cervical (71%) cancers were detected at an early stage but ovarian cancers (66.6%) in advanced stage. Chemotherapy and radiotherapy did not increase the risk of gynecological SM.
Conclusions: Women with BC are at risk of developing a second primary gynecological malignancy particularly of endometrium and ovary. Family history of BC was a high risk factor for gynecologic SM. These patients should be followed up for its early detection.
Similar articles
-
Nonbreast second malignancies after treatment of primary breast cancer.Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1489-92. doi: 10.1016/j.ijrobp.2008.07.004. Epub 2008 Sep 19. Int J Radiat Oncol Biol Phys. 2009. PMID: 18804919
-
Gynecological malignancy risk in colorectal cancer survivors: A population-based cohort study.Eur J Oncol Nurs. 2015 Oct;19(5):473-8. doi: 10.1016/j.ejon.2015.02.006. Epub 2015 Mar 16. Eur J Oncol Nurs. 2015. PMID: 25790918
-
Second primary in the contralateral breast after treatment of breast cancer.Radiother Oncol. 2008 Feb;86(2):171-6. doi: 10.1016/j.radonc.2007.10.002. Epub 2007 Oct 24. Radiother Oncol. 2008. PMID: 17961777
-
Epidemiologic analysis of breast and gynecologic cancers.Prog Clin Biol Res. 1997;396:17-29. Prog Clin Biol Res. 1997. PMID: 9108587 Review.
-
[Multiple primary cancers associated with gynecologic malignancies].Nihon Sanka Fujinka Gakkai Zasshi. 1990 Jun;42(6):561-6. Nihon Sanka Fujinka Gakkai Zasshi. 1990. PMID: 2205679 Review. Japanese.
Cited by
-
Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.Mol Biol Rep. 2019 Jun;46(3):3325-3332. doi: 10.1007/s11033-019-04794-8. Epub 2019 Apr 20. Mol Biol Rep. 2019. PMID: 31006098
-
Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer.Front Pharmacol. 2022 Jan 25;12:824531. doi: 10.3389/fphar.2021.824531. eCollection 2021. Front Pharmacol. 2022. PMID: 35145409 Free PMC article. Review.
-
HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.Trials. 2024 Jan 2;25(1):21. doi: 10.1186/s13063-023-07851-7. Trials. 2024. PMID: 38167339 Free PMC article. Clinical Trial.
-
Late-term effects of hypofractionated chest wall and regional nodal radiotherapy with two-dimensional technique in patients with breast cancer.Radiat Oncol J. 2020 Jun;38(2):109-118. doi: 10.3857/roj.2020.00129. Epub 2020 Jun 4. Radiat Oncol J. 2020. PMID: 33012154 Free PMC article.
-
Literature-Wide Association Studies (LWAS) for a Rare Disease: Drug Repurposing for Inflammatory Breast Cancer.Molecules. 2020 Aug 28;25(17):3933. doi: 10.3390/molecules25173933. Molecules. 2020. PMID: 32872166 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical